NASDAQ: ATONAlphaton Capital Corp Stock
$0.38-0.02 (-5%)
Updated Mar 13, 2026
ATON Price
$0.38
Fair Value Price
N/A
Market Cap
$2.19M
52 Week Low
$0.35
52 Week High
$15.82
P/E
-0.05x
P/B
0.23x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$14.89M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
2.26
Operating Cash Flow
-$4M
Beta
1.11
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
ATON Overview
Portage Biotech Inc. is a clinical-stage immuno-oncology company developing therapies to improve long-term treatment response and quality of life in patients with evasive cancers. The company's portfolio consists of five platforms leveraging delivery by (1) intratumorals, (2) nanoparticles, (3) liposomes, (4) aptamers, and (5) virus-like particles. Within these five platforms, the Company has 10 products under development. Portage Biotech was founded in 1973 and is headquartered in Tortola, British Virgin Islands.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine ATON's potential to beat the market
- ATON doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
ATON
RankedUnranked of 469
RankedUnranked of 469
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $14.51 | A | |
| $32.13 | A | |
| $178.55 | A |
Be the first to know about important ATON news, forecast changes, insider trades & much more!
ATON News
Overview
Due Diligence Score
–
Industry Average (25)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how ATON scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
ATON is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
ATON is good value based on its book value relative to its share price (0.23x), compared to the US Biotechnology industry average (4.7x)
P/B vs Industry Valuation
ATON is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more ATON due diligence checks available for Premium users.
Valuation
ATON fair value
Fair Value of ATON stock based on Discounted Cash Flow (DCF)
Price
$0.38
Fair Value
$1.41
Undervalued by
73.08%
ATON is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
ATON price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.05x
Industry
29.31x
Market
31.82x
ATON price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.23x
Industry
4.7x
ATON is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
ATON's financial health
Profit margin
Revenue
$0.0
Net Income
-$10.4M
Profit Margin
0%
ATON's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$30.6M
Liabilities
$21.7M
Debt to equity
2.26
ATON's short-term liabilities ($21.54M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
ATON's short-term assets ($19.02M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
ATON's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
ATON's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
N/A
Investing
N/A
Financing
N/A
ATON's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
ATON vs Biotech Stocks
Alphaton Capital Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.